Iodine supplementation: Recommendation, issued by the National Health Authorities, on supplementing with iodine (200 ug/day) women during preconception, pregnancy and lactation.
Full intellectual capabilities are achieved only if crucial nutrients are present during development. Iodine deficiency is the most common cause of preventable brain harm in infants. Because of its critical need during pregnancy, several countries implemented programs of iodine supplementation in preconception and pregnancy. In 2013, the prevalence of iodine deficiency in Portugal has led health authorities to issue a recommendation for iodine supplementation. This study aims to evaluate the impact of iodine supplementation on maternal and fetal iodine status and thyroid function, obstetric outcomes, quality of breast milk and child psychomotor development. It also intends to evaluate whether the time of iodine supplementation initiation influences all the above-mentioned parameters. The novelty and relevance of this study reside on the number of women/child and on the extent of health parameters that will be evaluated. The information collected will contribute to the detailed characterization of thyroid hormone homeostasis throughout pregnancy and its relationship with iodine supplementation (including time of initiation). The data will provide evidence on whether this iodine supplementation strategy impacted on iodine sufficiency of the mother and the newborns, or if it needs re-evaluation.
| Facility | City | Region | Status |
|---|---|---|---|
| Usf Maxisaude | Braga | Portugal | |
| Usf Braga Norte | Braga | Portugal | |
| Usf Ruães | Braga | Portugal | |
| Usf S. Lourenço | Braga | Portugal | |
| Usf Gualtar | Braga | Portugal | |
| Usf + Carandá | Braga | Portugal | |
| Usf Manuel Rocha Peixoto | Braga | Portugal | |
| Usf Bracara Augusta | Braga | Portugal | |
| Usf Do Minho | Braga | Portugal | |
| Usf S. João de Braga | Braga | Portugal |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04288531 on ClinicalTrials.gov ↗ ← All trials in Portugal